Prevalence of metabolic syndrome in women with polycystic ovarian syndrome: an observational study in a tertiary care centre in Pondicherry, India

Indu N. R., Hiremath P. B., Urmi Sanyal, Shilpa ., Rohini ., Reshma Hiremath


Background: Polycystic Ovarian Syndrome (PCOS) is a multifactorial, polygenic and multisystem endocrine disorder affecting women in reproductive age. PCOS diagnosis is based on 2003 Rotterdam criteria It has been noted that hyperinsulinemia is a central factor in the pathogenesis of PCOS. Many studies show evidence of a critical link between PCOS and Metabolic Syndrome (MBS).

Methods: It was a hospital - based observational study done over a period of one year with a sample size of 177.An observational study was done in patients satisfying the inclusion and exclusion criteria. After taking informed and written consent, history was obtained from the patient to know the age, socioeconomic status, present and past clinical history, menstrual and obstetric history, personal and family history and any other history as deemed necessary. Patient was clinically assessed to know the height, weight, body mass index.

Results: The prevalence of MBS was 37.2%. The commonest age group was between 25- 35 years.There is no statistical association between educational qualification, economic status and the prevalence of MBS and There no significant association between the presence of acne, androgenic aloepecia and the presence of PCOS.While the presence of increased waist circumference > 88cms, USG findings consistent with PCOS, high blood pressure > 130/85 mm of Hg, elevated FBS > 110 mg/dl, low HDL <50 mg/dl were statistically significant.

Conclusions: The results can be used to formulate a screening policy for metabolic syndrome, particularly in the low resource settings of developing countries.


Hirsutism, Hypertension, Metabolic syndrome, Menstrual irregularities, Obesity, Polycystic ovaries

Full Text:



Dey R, Mukherjee S, Roybiswas R, Mukhopadhyay A, Biswas SC. J Obstet Gynaecol India. 2011;61(2):176-81.

Mandrelle K, Kamath MS, Bondu DJ, Chandy A, Aleyamma T, George K. Prevalence of metabolic syndrome in women with polycystic ovary syndrome attending an infertility clinic in a tertiary care hospital in south India. J Hum Reprod Sci. 2012;5(1):26-31.

Moini A, Javanmard F, Eslami B, Aletaha N. Prevalence of metabolic syndrome in polycystic ovarian syndrome women in a hospital of Tehran. Iran J Reprod Med. 2012;10(2):127-30.

Kandaraki E, C Christakou, E Diamanti. Metabolic syndrome and polycystic ovary syndrome and vice versa. Arq Bras Endocrinol Metabol. 2009;53(2):227-37.

Barber MT, McCarthy MI, Franks S, Wass JAH. Metabolic syndrome in polycyctic ovary syndrome. Pol J Endocrinol. 2007;(58)1:34-41.

Akshaya S., Ratnaboli Bhattacharya. Comparative study of clinical profile of lean and obese polycystic ovary syndrome women Int J Reprod Contracept Obstet Gynecol. 2016;5(8):2530-3.

Dokras A. Cardiovascular disease risk in women with PCOS. Steroids. 2013;31;78(8):773-6.

Mak W, Dokras A. Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. In Sem Thromb Hemostat. 2009;35(7):13-20.

The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9.

Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome:a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84(1):165-9.

Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE et al Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000;20(11):2414-21.

Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long term follow-up.J Clin Epidemiol. 1998;51(7):581-6.

HaeffnerSM, ValdezRA, HazudaHP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715-22.

Reaven GM. Role of insulin resistance in human disease. Diab. 1988;37(12):1595-607.

Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard J, et al. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report.Circulat. 2002;106(25):3143-421

Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366(9491):1059-62.

Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clinic Endocrinol Metabol. 2006;91(1):48-53.

Dokras A, Bochner M, Hollinrake E, Markham S, VanVoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. 2005;106(1):131-7.

Rabelo AM, Vick MR. Association between the PCOS and the metabolic syndrome in Puertorico.PR Health Sci J. 2005;24(3):203-6.

Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and char- acteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929-35.

Misra A, Wasir JS, Pandey RM. An evaluation of candidate definitions of the metabolic syndrome in adult Asian Indians. Diab Care 2005;28:398-403.